SCHEMBL21536261

SCHEMBL21536261

O=C(c1cc(-c2ccco2)on1)N1CC(F)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 8/20 0.72
SCD O00767 5/20 0.72
ALDH1A1 P00352 7/20 0.67
RAB9A P51151 5/20 0.67
CYP1A2 P05177 1/20 0.67
NPC1 O15118 4/20 0.66
HPGD P15428 2/20 0.65
MAPT P10636 5/20 0.61
POLB P06746 4/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
LMNA P02545 2/20 0.61
USP2 O75604 3/20 0.60
ALOX15 P16050 2/20 0.60
RECQL P46063 2/20 0.60
HSD17B10 Q99714 2/20 0.60
TSHR P16473 2/20 0.60
ESR1 P03372 1/20 0.60
PKM P14618 1/20 0.60
BLM P54132 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21523598 0.84 SCD5 (1.00) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21535885 0.81 RAB9A (0.78) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21536253 0.81 SCD5 (0.70) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21523749 0.81 SCD5 (1.00) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21523803 0.81 SCD5 (1.00) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21536505 0.80 RAB9A (1.00) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21536304 0.77 SCD5 (1.00) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL28909938 0.77 SCD5 (0.77) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21536507 0.77 SCD5 (0.78) SCD5SCDALDH1A1RAB9ACYP1A2
SCHEMBL21536275 0.77 SCD5 (0.95) SCD5SCDALDH1A1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919885-B2 Compounds and uses thereof YUMANITY THERAPEUTICS, INC. (US) 2021-02-16 US disclosed
US-20190330198-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919885-B2 Compounds and uses thereof NLN, ACHE, CLN6 SCD5 1575/4885SCD 2044/4885ALDH1A1 656/4885
US-20190330198-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SCD5 1575/4885SCD 2044/4885ALDH1A1 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.